Screener / SEC EDGAR /CIK 0001581280 /10-K filed Nov 17, 2025, compared with Nov 18, 2024 /Numbers from the XBRL of the 10-Ks
Health care peers:
Nasdaq Health care · Biotechnology

Twist Bioscience Corp TWST

At Twist Bioscience Corporation, we work in service of our customers who are changing the world for the better. 10-K, Item 1

Headquarters
South San Francisco, CA
CEO
Emily M. Leproust
Next results
around Jan 11, 2027
Compare with peers Embed

TWST among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.

Compare
Revenue growth: 20.3%, above 76% of 154 peers (their median 10.4%) REVENUE GROWTH 20.3% · above 76% Gross margin: 52.0%, above 28% of 107 peers (their median 63.8%) GROSS MARGIN 52.0% · above 28% Operating margin: -33.6%, above 14% of 138 peers (their median 10.2%) OPERATING MARGIN -33.6% · above 14% Net margin: -31.7%, above 15% of 153 peers (their median 6.8%) NET MARGIN -31.7% · above 15% FCF margin: -21.6%, above 14% of 144 peers (their median 10.1%) FCF MARGIN -21.6% · above 14%
TWST Peer median Below the median

What changed

14 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Nov 17, 2025 against Nov 18, 2024.

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

1fact worth reading about the other 10 checks found nothing to note

  • Receivables growing faster than revenue
    Receivables +63.4% ($34.9M to $57.0M) vs revenue +20.3% ($313.0M to $376.6M), +43.0 pts apart
  • Cash from operations −$47.6M vs net income −$77.7M (FY ending Sep 30, 2025)
9 more checks with nothing to note
  • Inventory +17.6% ($24.1M to $28.3M) vs revenue +20.3% ($313.0M to $376.6M), -2.7 pts apart
  • Same auditor in both 10-Ks: Ernst & Young LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • The same matters as last year: Revenue recognition
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

14 paragraphs in Risk Factors that were not in the 10-K filed Nov 18, 2024. Quoted as filed.

All 14 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Nov 18, 2024 10-K, ITEM 1A
    As we continue to grow our business, we will need to implement new systems and software successfully, otherwise our business and our financial condition and results of operations could be adversely affected. We will need to invest in improvements to our operational and IT systems and processes as part of our ongoing effort to improve…
  2. Item 1A · new paragraph · not in the 10-K filed Nov 18, 2024 10-K, ITEM 1A
    AI capabilities may indicate that it could be a significant disruptor in the synthetic biology industry. For example, AI may reduce customer demand for certain types of gene synthesis.
  3. Item 1A · new paragraph · not in the 10-K filed Nov 18, 2024 10-K, ITEM 1A
    The global economy has been impacted by geopolitical tensions. For example, new U.S. federal administration has recently imposed significant new tariffs on imports, which, along with other U.S. trade actions, have triggered retaliatory actions by certain affected countries. These geopolitical tensions could result in, among other…
  4. Item 1A · new paragraph · not in the 10-K filed Nov 18, 2024 10-K, ITEM 1A
    We may not achieve the anticipated benefits from the spin out of our DNA data storage application. In May 2025, we completed the spin out of our DNA data storage application to a new independent company, Atlas Data Storage (“Atlas”), which allows us to focus on our synthetic biology, NGS and biopharma products and services. While we…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$203.6M$245.1M$313.0M$376.6M
Net income−$217.9M−$204.6M−$208.7M−$77.7M
Operating cash flow−$124.4M−$142.5M−$64.1M−$47.6M
Free cash flow−$226.2M−$170.3M−$69.2M−$75.6M

Revenue, FY2017 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$376.6M ▲ 20.3% in FY2025

FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

7 filings in the last 30 days · SEC EDGAR

All filings
2 more

About the company

Twist Bioscience Corp, South San Francisco, CA · from the 10-K filed Nov 17, 2025

At Twist Bioscience Corporation, we work in service of our customers who are changing the world for the better. In fields such as health care, food/agriculture, industrial chemicals/materials and academic research, by using our products, our customers are developing ways to better lives and improve the sustainability of the planet. We believe Twist Bioscience is uniquely positioned to help accelerate their efforts and the faster our customers succeed, the better for all of us.

Headquarters
South San Francisco, CA
Country
United States
Reports in
USD
Listed on
Nasdaq
Fiscal year ends
September 30
Last results
Nov 12, 2026
Incorporated in
DE

Email alerts

Sources

The 10-K filed Nov 17, 2025 (open at SEC), compared with the 10-K filed Nov 18, 2024. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/TWST/export.csv") into a cell.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.